文献速递免疫规划慢病防控与筛查

单克隆B细胞增多症与慢性淋巴细胞白血病患者对高剂量流感疫苗的体液免疫应答

The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).
PubMed 文献 · Vaccine · 2021-01-16

该前瞻性先导研究评估了2013-2014和2014-2015年度高剂量三价流感疫苗在单克隆B细胞增多症(MBL)和未经治疗的慢性淋巴细胞白血病(CLL)患者中的体液免疫应答。共纳入30例受试者(17例CLL,13例MBL),中位年龄69.5岁。结果显示该人群疫苗免疫原性低于健康成人报道水平,且MBL患者对乙型流感疫苗株的免疫应答优于CLL患者。

要点

  • CLL和MBL患者接种高剂量流感疫苗后免疫原性低于健康成人。
  • MBL患者对乙型流感疫苗株的血清保护率和抗体滴度均高于CLL患者。

核心结论

  • 高剂量三价流感疫苗在CLL和MBL患者中的免疫原性低于健康成人报道水平。
  • MBL患者对乙型流感疫苗株的免疫应答优于CLL患者。

研究设计与样本

  • 前瞻性先导研究,纳入30例受试者(17例CLL,13例MBL),中位年龄69.5岁。
  • 接种2013-2014和2014-2015年度高剂量三价流感疫苗(HD IIV3;Fluzone® High-Dose;Sanofi Pasteur)。
  • 基线及接种后第28天检测血清血凝抑制(HAI)抗体滴度,并采用B细胞酶联免疫斑点试验评估记忆B细胞应答。

主要发现

  • 第28天队列血清保护率:A/H1N1为19/30(63.3%),A/H3N2为21/23(91.3%),乙型流感为13/30(43.3%)。
  • MBL患者第28天针对乙型流感疫苗株的HAI几何平均滴度高于CLL患者(54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1];p=0.01)。
  • MBL患者第28天针对乙型流感疫苗株的血清保护率高于CLL患者(76.9% vs. 17.6%;p=0.002)。

临床怎么用

  • 提示CLL和MBL患者接种高剂量流感疫苗后仍需关注其免疫保护效果可能不足。
  • MBL与CLL患者对乙型流感疫苗株的应答存在差异,评估疫苗效果时需考虑疾病类型。

局限性

  • 样本量较小(共30例),为前瞻性先导研究。
  • 仅评估了2013-2014和2014-2015年度高剂量三价流感疫苗的体液免疫应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL). METHODS: A prospective pilot study of humoral immune responses to 2013-2014 and 2014-2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays. RESULTS: Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL. CONCLUSIONS: Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Whitaker JA, Parikh SA, Shanafelt TD, et al. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine. 2021. PMID: 33461835. doi:10.1016/j.vaccine.2021.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。